Pfizer plans to request authorization for its coronavirus vaccine for children aged 2-11 by September. The company also expects to hear back from the FDA “shortly” on whether its vaccine will be authorized for 12-15-year-olds.
Extra: The announcements were made during the company’s Q1 earnings call, during which it noted that the coronavirus vaccine accounted for $3.5B (24% of Q1 revenue).
The New Paper
This story is from the May 5, 2021 edition of The New Paper – a clear, concise daily briefing that makes fact-first news easy to consume. Try it today.
